Leo Cancer Care and Terapet Bring Real-Time In Vivo Treatment Verification to Particle Therapy

Collaboration to integrate PET-based verification technology within the Marie® system, enhancing precision and confidence in cancer treatment delivery 

CRAWLEY, UNITED KINGDOM & GENEVA, SWITZERLAND – 16 MAY 2026 – The collaboration between Leo Cancer Care and Terapet aims to offer advanced treatment verification capabilities, bringing real-time, patient-specific treatment validation closer to clinical practice. 

Terapet’s QUALYSCAN platform uses positron emission tomography (PET) to measure treatment accuracy, improving confidence in treatment efficacy for both clinician and patient. Initially developed as a high-precision quality assurance (QA) system, Terapet’s QUALYSCAN technology is now advancing toward an in vivo solution designed for integration directly into Leo Cancer Care’s Marie® system. This collaboration will enable seamless verification immediately. 

“Our partnership with Leo Cancer Care and RaySearch marks an important step in extending QUALYSCAN technology from machine and patient QA into in vivo verification, bringing treatment planning and delivery into a single, consistent framework through an innovative upright treatment platform,” Christina Vallgren, CEO and Co-Founder of Terapet. 

The integrated solution is designed to enable: 

• Immediate verification of treatment delivery after irradiation 

• Patient-specific validation beyond conventional pre-treatment QA 

• Early detection of deviations between planned and delivered dose 

• Increased confidence in treatment accuracy for clinicians and patients 

• Potential to enable adaptive therapy workflows, using real-time insights to inform subsequent treatment fractions 

By integrating verification directly within Leo Cancer Care’s upright therapy platform and utilising RaySearch’s treatment planning software, RayStation®, the partnership brings together treatment planning, delivery and validation into a unified ecosystem. 

“This partnership allows us to rethink the relationship between the machine and the patient. By merging verification with delivery, we’re removing technical barriers for the user to create a more efficient, confident environment where precision becomes embedded in the workflow”, Mark Strangeman, VP of Engineering at Leo Cancer Care. 

The collaboration underscores the companies’ commitment to advancing patient-centric innovation in radiation therapy. This partnership marks a step forward in treatment verification and workflow integration, supporting more personalised treatments in the near future. 

Make sure to find out more if you are attending ESTRO 2026 in Stockholm, Sweden, by visiting Leo Cancer Care at booth C11:31, where a Terapet representative will be on hand to offer more information on the QUALYSCAN Upright Solution. The conceptual solution will also be presented on the ESTRO stage – Add to calendar

Please note:

This QUALYSCAN Upright solution is currently under development and is not commercially available or approved for clinical use. Images are purely a conceptual illustration.